Volume 2, Issue 1 (click here to download the full pdf version)

Message from the President

Pathology is a medical specialty integrating personal experience and cutting-edge techniques. As a professional body committed to the upkeep and assurance of high-quality pathology practices, our College is dedicated to equipping our fellows with the ability to meet the challenges of evolving advancement in techniques and increasing expectation of the community. Concurring with the initiative by Hong Kong Academy of Medicine to promote training in genetics and genomics in several specialties, our College has been working on establishing a post-specialty fellowship in Genetic and Genomic Pathology under a special task force led by Dr Michael CHAN involving Specialty Board Chairpersons, Chief Examiners and representatives from various pathology specialties. Continued input of opinions from fellows and trainees is important.

We are encouraged by the success of the International Pathology Day Workshops targeted at high school students. The success is attributed to the hard work of a team of young fellows and trainees from various pathology specialties under the leadership of Dr Leon LAI. This year, such a workshop will be conducted again at around 15 November 2017. We shall continue to count on selfless support from fellows and trainees.

The College will continue to enhance communication with overseas and local professional bodies. There are representatives of our College in advisory groups in local administrations, and regular meetings with sister colleges overseas will continue.

The future of the profession and the College lies with our young fellows. The Academy is forming a Young Fellows Chapter for better engagement in the Academy’s activities. Each college is asked to nominate one fellow who has been conferred fellowship within the past 10 years. Dr MAK Siu Ming has been nominated to serve the first term (one year) of this Chapter.

The time of succession has also come. Nomination for Office Bearers and Councillors will be open soon. Your active participation is crucial for the success and prosperity of the pathology profession.

Professor CHEUNG Nga Yin, Annie May 2017

Laboratory testing for Direct Oral Anticoagulants (DOACs):

Are we ready?

 

Volume 12, Issue 1 January 2017  (download full article in pdf)

 

Editorial note:

In this topical update, Dr Rock Leung reviews the testing strategy and quality assurance issues on laboratory testing for direct oral anticoagulant (DOACs). We welcome any feedback or suggestions. Please direct them to Dr Rock Leung (e-mail: leungyyr.ha.org.hk) of Education Committee, the Hong Kong College of Pathologists. Opinions expressed are those of the authors or named individuals, and are not necessarily those of the Hong Kong College of Pathologists.

 

Dr. Rock LEUNG
Associate Consultant, Division of Haematology, Department of Pathology and Clinical Biochemistry
Queen Mary Hospital, Hong Kong

 

Abbreviations

DOACs	Direct oral anticoagulants
FIIa	Thrombin
PK	Pharmacokinetics
PD	Pharmacodynamics
PT	Prothromhin time
APTT	Activated partial thromboplastin time
TT	Thrombin time
dTT	Diluted thrombin time
ECT	Ecarin clotting time
DRVVT	Diluted Russell’s viper venom time

 

Introduction

The newly available Food and Drug Administration (FDA) -approved oral anticoagulants, namely dabigatran extexilate, rivaroxaban, apixaban and edoxaban, have been more commonly used nowadays for treatment and prophylaxis of venous thromboembolism, as well as for prevention of stroke in non-valvular atrial fibrillation. This new class of anticoagulants has been referred as novel oral anticoagulants (NOACs), target-specific oral anticoagulants (TOACs), or direct oral anticoagulants (DOACs). For the sake of standardization, the International Society for Thrombosis and Haemostasis (ISTH) Scientific and Standardization Committee (SCC) for the control of anticoagulation recommends the term DOACs. DOACs have been shown to be at least as effective as warfarin in various clinical trials. Moreover, there was reduced incidence of intracranial haemorrhage reported in some studies when compared with warfarin [1]. Unlike warfarin, DOACs do not need routine therapeutic monitoring given their predictable pharmacokinetics (PK), pharmacodynamics (PD) and wide therapeutic windows. There are, however, clinical conditions that measurement of anticoagulation activity of DOACs is necessary or potentially useful, e.g. before invasive procedures, during adverse events like break-through bleeding or thrombosis, and pre- and post-administration of reversal therapy for patients with DOACs overdose. Thus, there is a role for laboratory, by testing for DOACs, to help clinicians on patient management. In addition, it is the responsibility of the laboratory to acknowledge the interferences of DOACs on conventional and special coagulation tests as part of the laboratory quality assurance in the era of gaining popularity of DOACs usage.

 

Mechanisms of actions of DOACs

In contrast with heparin that can only inhibit free protease, DOACs are rapidly-acting, target-specific anticoagulants that inhibit both the free and bound activated serine protease [2]. The fact that DOACs can inactivate bound serine protease explains their more robust action than warfarin or heparin. Dabigatran is a direct thrombin (IIa) inhibitor while rivaroxaban, apixaban and edoxaban are direct inhibitors of activated factor X (Xa). Most of the DOACs are cleared by liver and kidney, with the exception of dabigatran being almost exclusively excreted by kidney. DOACs reach peak plasma levels within approximately two hours and plasma trough levels within 12 hours or 24 hours depending on their frequency of administration [3]. The DOACs can be withhold a few days before elective surgery or invasive procedures due to their short half-lives and favourable pharmacokinetics.

 

To test or not to test?

Routine monitoring of DOACs is not required. Testing on patients on DOACs is generally indicated in certain clinical circumstances, including acute bleeding, suspected DOACs overdose, drug interaction, in patients with impaired renal function, before surgery or invasive procedure in patients who have taken the drug beyond 24 hours and with creatinine clearance of <50 mL/min or with extreme body weight [4]. Recently, more pharmacokinetics and pharmacodynamics data on indications of clinical testing came up. Currently it is recommended that checking of drug-specific peak and trough levels for DOACs should be performed for patients with body mass index (BMI) of >40 kg m^2 or weighted over 120 kg [5]. There is currently no consensus on when to test for DOACs activities when these drugs are to be used in women with childbearing potential. One should however note that animals studies have shown teratogenic effect of dabigatran, edoxaban and rivaroxaban, these drugs were assigned by the FDA as pregnancy category C, reflecting their potential teratogenicity. Whereas no teratogenicity has been demonstrated in animals for apixaban as of today, it was categorized as pregnancy catergory B by FDA [6]. On the other hand, the use of DOACs is considered an off-label clinical application for paediatric thromboemobolic diseases [7]. It is not unreasonable to obtain information about anticoagulation activity by laboratory assay for this special group of patients, as in the case of low-molecular-weight heparin (LMWH) usage in select paediatric patients.

Given the predictable pharmacokinetics of DOACs, it was proposed that a pharmacokinetic strategy by stopping the drug for a time frame adequate for washout of drug effect is safe before surgery or invasive procedures. This approach can only be applied for planned surgery or invasive procedures, with available information regarding patient’s renal function as well as the dose and timing of the last DOAC administration. For emergent or unplanned procedures in patients with renal insufficiency or unplanned procedures when the timing of the last DOAC administration is uncertain, measurement of residual drug level will be valuable to assist clinical decisions, including the assessment of bleeding risk and the need for antidote for prompt reversal of DOAC effect before surgery. In life-threatening bleeding associated with the use of DOACs, the measurement of drug level can supplement clinical information to determine whether the bleeding is contributed by the anticoagulation effect of DOACs and whether the administration of DOAC-specific antidotes is required. If antidote is applied, laboratory test can monitor the extent of reversal.

 

What tests to do?

The ideal test for DOACs shall be accurate, readily available on a 24-hour basis in order to accommodate emergency clinical situations, and with a reasonably short turnaround time (TAT).
Gold standard method using ultra-performance liquid chromatography – tandem mass spectrometry (UPLI-MS/MS) provides the most accurate information about the drug levels for patients on DOACs. However, the test is not readily available in most of the laboratories.

Routine coagulation screening tests, i.e., prothrombin time (PT), activated partial thromboplastin time (APTT) or thrombin time (TT), have been suggested as screening tests for DOACs. For routine coagulation screening tests to be useful and suitable for testing for DOACs, linearity and adequacy of test response to increasing dosage and amenability to standardization are prerequisites [8]. For dabigatran, TT is readily available in most laboratories and prolongation of clotting time is linearly and dose-dependently related to dabigatran concentrations. However, responsiveness is excessive. Therefore, a normal TT should rule out a dabigatran anticoagulant effect but the degree of prolongation poorly reflects drug concentration. Dilute TT (dTT), i.e., testing of TT on diluted plasma, is adequately responsive to dabigatran and suitable for assessment of dabigatran activity. Ecarin clotting time (ECT), using ecarin for the conversion of FII to meizothrombin, to assess anticoagulant effect of dabigatran was also shown to have satisfactory linearity and responsiveness to increasing dabigatran concentrations. APTT, though being demonstrated to have satisfactory responsiveness to dabigatran, lacks linearity upon increasing drug concentration and there is significant inter-reagent variability [9]. PT is insensitive to dabigatran and not suitable for testing.

Rivaroxaban prolongs the PT in a concentration-dependent manner, but the correlation is generally weak and became weaker with increasing drug concentration. Significant reagent-dependent differences in assay sensitivity are noted in multiple studies, limiting its use for assessment of rivaroxaban activity if the in-house thromboplastin reagent for routine coagulation screening is insensitive to rivaroxaban [10]. APTT is insensitive to rivaroxaban and shall not be used for assessment of rivaroxaban activity. For apixaban, both PT and APTT are insensitive to increasing drug concentrations and for edoxaban, PT performance is similar to that observed for rivaroxaban and APTT is insensitive [11].
Therefore, routine coagulation screening tests PT, APTT and TT cannot provide a reliable measurement of DOAC anticoagulant effect in most circumstances. One exception being a normal TT excludes significant residual effect of dabigatran in patients. Moreover, PT and APTT are either insensitive or show variably sensitivity to the on-therapy range of DOACs and limit their use in determining whether the drug concentration is in subtherapeutic or supratherapeutic ranges. Furthermore, these coagulation screening tests are potentially affected by the presence of lupus anticoagulants and conditions resulting in factor deficiency as in liver disease or dilutional coagulopathy. Thus, the sensitivity & specificity in reflecting the anticoagulant effect of DOACs is limited.

Anti-Xa assay is a chromogenic assay based on the measurement of residual FXa with synthetic substrates upon mixing of plasma with FXa. Although one study showed the feasibility of using of anti-Xa assay for LMWH to assess the presence of rivaroxaban [12], it is recommended to use drug-specific calibrator rather than adopting the anti-Xa assay for measurement of heparin activity due to the following reasons: 1) assays to measure indirect Xa inhibitors, e.g., LMWH, are measured in IU/ml and direct Xa DOACs are measured in ng/mL and there is no direct relationship between these two units of measure, 2) there is significant variability in measured drug concentration, as demonstrated by rivaroxaban, between various anti-Xa kits and 3) the therapeutic range, at least for apixaban and rivaroxaban, far exceeds the typical calibration range for UFH and LMWH (in the 5-9 IU/ml range) and 4) the assay is not specific for anti-Xa DOACs and will detect all anti-Xa anticoagulants2.

Commercially available drug-specific coagulation assays for testing of DOACs use calibrators and controls specific for the DOAC being measured [13-15], enabling the reporting of a drug concentration upon testing of patient’s plasma sample. Multiple calibrators and test plasma dilutions are employed to ensure the test sample responses are within the range of the calibration curve and also to allow for assessment of linearity and parallelism [16]. It was recommended that anti-Xa assay and diluted TT shall be employed when carrying out the drug-specific coagulation assay for anti-Xa inhibitor and anti-IIa inhibitor respectively, given their linear relationship and good correlation with drug concentration as measured by mass spectrometry [11]. Although an ecarin chromogenic assay (ECA) for direct IIa inhibitor and a DRVVT-based assay for both direct IIa and direct Xa inhibitors have been calibrated for testing of DOACs, ECA was shown to have suboptimal accuracy when compared UPLC-MS/MS and DRVVT-based assay would give false positive result in the presence of lupus anticoagulant [17,18]. Studies have shown that various drug-specific coagulation assays differ significantly in quantitation of the DOAC being measured when compared with UPLC-MS/MS in terms of precision and accuracy [17].

 

What is the meaning of drug concentration?

Drug-specific assay is by no means a direct measurement of drug concentration for DOACs. Instead it is an extrapolation of drug concentration by its anticoagulation activity measured by clot-based or chromogenic assay.
Therapeutic ranges of DOACs have not been validated by the manufacturing pharmaceutical companies. Moreover, there is no established range of concentrations associated with bleeding. In clinical use, expected trough and peak concentrations as predicated on prescribed dose and frequency are often taken as a reference during result interpretation of drug levels [17] (Table 1).

 

There is no consensus on whether trough level is superior to peak level when interpreting the findings during monitoring of DOACs. The sample for DOAC level is often collected at a random time during emergency clinical situations. A meaningful interpretation of drug level requires the knowledge of the time of last dose of DOAC, the drug dosage and patient’s renal and liver functions so that the trend of drug concentration over time can be better predicted.
With increasing use of DOAC assay, it is expected that DOAC plasma concentration shall be a standard study parameter in future clinical trials. This will allow the identification of drug concentration threshold associated with bleeding, the establishment of a therapeutic range for different kinds of DOACs and better definition of DOAC-induced bleeding complications.

 

Antidote for reversal of DOACs

Non-specific reversal agents like prothrombin complex concentrates, “bypassing agent” like factor eight inhibitor bypass activity (FIBA) and activated FVIIa were used for the correction of DOAC effect. They only had a general antagonizing action on the anticoagulation effect of DOAC without targeting the specific DOACs themselves. Three antidotes for the DOACs are now under various stages of development. Idarucizumab (Praxbind®), the antidote for dabigatran, is now licensed in the United States and recommended for licensing by the European Medicines Agency. Andexanet alfa, the antidote for the oral anti-Xa inhibitors, is undergoing phase III study. Ciraparantag (PER977), an agent reported to reverse the anticoagulant effects of all of the DOACs is at an earlier stage of development [19]. In life-threatening bleeding, administration of antidote or reversal agent before emergency operations shall not be delayed until the availability of test results. Otherwise, the decision on whether antidote is indicated can be guided by suitable laboratory assay as mentioned in the previous section. Drug-specific assay is considered the most suitable candidate given its superior sensitivity and probably better specificity than conventional coagulation assay and better accessibility and faster turnaround compared with mass spectrometry. Measurement of drug activity shall guide the antidote treatment and allow more effective use of this costly medicine. The importance is highlighted by one study on idaruxizumab for dabigatran reversal in which dTT was normal on study entry in nearly one quarter of the study population, indicating little or no circulating anticoagulant in this group of patients, whom benefit from the administration of idaruxizuman was minimal [20]. Although DOAC concentrations warranting the administration of antidote were recommended (e.g., a drug concentration over 50 ng/mL in serious bleeding and 30 ng/mL in patients requiring urgent intervention) [19], these actionable limits have not been validated in clinical studies.

 

Quality assurance issues on DOACs testing

Laboratories should develop customized algorithms on DOACs testing strategy for DOACs based on their need. The relative sensitivity of routine coagulation screening test, especially APTT and TT for dabigatran and PT for rivaroxaban, apixaban and edoxaban shall be validated by calibrated materials. Most published algorithms [21, 22] assume patient’s coagulation status is solely under the effect of DOACs and may not be applicable for patients with massive transfusion, disseminated intravascular coagulopathy (DIC) or presence of lupus anticoagulant that may have contributed to the abnormal coagulation screening results. Moreover, it is not practical to change the service PT and APTT reagents solely for DOACs detection.
The set up of clot-based or chromogenic drug-specific assay needs careful literature review on the performances of different commercially available assays. For example, one study reported overestimation of rivaroxaban levels with an anti- Xa assay utilizing exogenous antithrombin [23] and ISTH [4] recommended against its use. Nevertheless, the choice of commercially available assay may be limited by its compatibility with the automated coagulometers in service.
There are currently no standards or guidelines on the validation of drug-specific coagulation assays. Same principles on validation for clot-based or chromogenic coagulation assay shall follow, including testing for accuracy, within-run & between-run precisions and lower limit of quantification (LOQ). The testing of accuracy may be limited by accessibility to mass spectrometry. This can be resolved by testing accuracy against different lot of calibrators. Precision at low drug concentration is important to determine any significant residual DOAC effect in emergency setting. Assay kit with incorporation of low-level calibrators is favored over those with calibrators only covering the usual on-therapy concentration ranges. For the same reason, LOQ validation is important and the report shall report results as “less than” numerical LOQ value (ng/mL). Testing on plasma collected from normal subjects not taking DOACs shall be carried out to determine the intrinsic anti-Xa or anti-IIa activity from natural anticoagulant, e.g., antithrombin, which may also affect the lowest reportable limit of the assay.

As part of the quality assurance, PT, APTT, TT and fibrinogen activity shall be assessed for samples sent for quantitation of DOACs. When TT is prolonged, heparin contamination shall be excluded by carrying out protamine neutralization test. Before reporting the drug concentration, linearity of the calibrator curves shall be verified. Calibrator curve shall be acquired for every patient sample instead using stored calibrator curves as a control of lot-to-lot variation of calibrators for this relatively infrequent test. Results shall be reported in ng/mL, and there should be an accompanied comment about the appropriate range of results (peak or trough levels) based on publication. Drug level shall be interpreted in light of the time since last dose of DOAC intake as well as the dosage of DOAC taken. It is critical to have continuous surveillance of test performance over time. This can be achieved through enrollment in External Quality Assurance Programme (EQAP) (e.g., College of American Pathologist).

Drug-specific coagulation assay can be performed by automated coagulometers with pre-set dilution and analysis protocols with a low to moderate level on skill requirement and hence amenable to the organization of a laboratory-wide staff training programme to cater for the development of a routine 24-hour DOAC laboratory testing service. Interval refreshment training shall be organized to upkeep staff competence. Clinical pathologists shall be involved in communication with clinicians during emergency management of patients requiring DOAC testing to ensure efficient delivery of accurate information to facilitate patient management.

 

Impact of DOACs on special coagulation assay

It is important for laboratories that carry out special coagulation assay to acknowledge the interferences of DOACs on special coagulation assay. These include clot-based and chromogenic assay. ELISA-based and molecular assays are essentially not affected by DOACs (Table 2) [2, 17].

 

Conclusion

DOACs are more commonly used nowadays. While clinical indications for laboratory testing are more available, there is a pivotal role of laboratories to formulate a testing strategy for DOACs. Routine coagulation screening tests are not informative in most cases. Development of drug-specific assay for DOACs testing is needed. The interpretation of drug level generated by drug-specific assays needs to be facilitated by more data on the association between drug concentrations and bleeding risks expected in future studies.

 

Table 1. 5th – 95th percentile of peak and trough concentrations of DOACs obtained from pharmacokinetic and pharmacodynamics studies on patients prescribed with fixed dose and frequency of DOACs.

	Trough (ng/mL)	Peak (ng/mL)
Apixaban 2.5 mg twice daily 10 mg twice daily	20-94 30-412	36-100 122-412
Dabigatran 150 mg twice daily	31-225	64-223
Edoxaban 30 mg once daily 60 mg once daily	130-174 268-336	376-412 388-444
Rivaroxaban 10 mg once daily 20mg once daily	1-38 4-96	91-195 160-360

 

Table 2. Impact of DOACs on select special coagulation assays

Assay	Anti-FIIa DOAC	Anti-FXa DOAC
Clauss fibriongen	May be falsely decreased	No effect
One-stage APTT-based factor assays	May demonstrate false decrease in factor activity	May demonstrate false decrease in factor activity
One-stage PT-based factor assays	May demonstrate false decrease in factor activity	May demonstrate false decrease in factor activity
Chromogenic FVIII activity	No effect	May demonstrate false decrease in factor activity
Bethesda assay	False inhibitor present	False inhibitor present
AT activity: thrombin substrate	May demonstrate false increase in AT activity; may mask AT deficiency	No effect
AT activity: FXa substrate	No effect	May demonstrate false increase in AT activity; may mask AT deficiency
PC activity: clot based	May demonstrate false increase in PC activity; may mask PC deficiency	May demonstrate false increase in PC activity; may mask PC deficiency
PC activity: chromogenic	No effect	No effect
PS activity: clot-based	May demonstrate false increase in PS activity; may mask PS deficiency	May demonstrate false increase in PS activity; may mask PS deficiency
PS activity: chromogenic	No effect	No effect
PS activity: ELSA-based or LIA-based	No effect	No effect
LA testing	Possible to misclassify as LA present	Possible to misclassify as LA present
Activated PC resistance	Falsely increased ratio; possible to misclassify as FV Leiden mutation absent	Falsely increased ratio; possible to misclassify as FV Leiden mutation

AT, antithrombin; PC, protein C; PS, protein S, LA, lupus anticoagulant; LIA, latex immunoassay

 

References

1. Bauer KA. Targeted anti-anticoagulants. N Engl J of Med 2015;273:569-571.
2. Adcock DM, Gosselin R. Direct Oral Anticoagulants (DOACs) in the Laboratory: 2015 Review. Thromb Res 2015;136:7-12.
3. Schulman S. New oral anticoagulant agents – general features and outcomes in subsets of patients. Thromb Haemost 2014;111:575-582.
4. Baglin T, Hillarp A, Tripodi A, et al. Measuring oral direct inhibitors of thrombin and factor Xa: a recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2013;11:756–760.
5. Martin K, Beyer-Westendorf J, Davidson BL, et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J Thromb Haemost 2016;14:1308-1313.
6. Desborough MJ, Pavord S, Hunt BJ. Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH: comment. J Thromb Haemost 2016; 27:1-2.
7. von Vajna E, Alam R, and So TY. Current Clinical Trials on the Use of Direct Oral Anticoagulants in the Pediatric Population. Cardiol Ther 2016;5:9–41.
8. Tripodi A. The laboratory and the direct oral anticoagulant. Blood 2013;121:4032-4035.
9. Stangier J, Rathgen K, Stahle H et al. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral directed thrombin inhibitor, in healthy male subject. Br J Clin Pharmacol 2007;64: 292-303.
10. Kitchen S, Gray E, Mackie I et al. BCSH committee. Measurement of non-coumarin anticoagulants and their effects on tests of Haemostasis: Guidance from the British Committee for Standards in Haematology. Br J Haematol 2014;166:830-841.
11. Samuelson BT, Cuker A, Siegal DM et al. Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants (DOACs): A Systematic Review. Chest. 2016 Sep 13. pii: S0012-3692(16)59148-X. doi: 10.1016/j.chest.2016.08.1462.
12. Yates SG, Smith S, Tharpe W et al. Can an anti-Xa assay for low molecular weight heparin be used to assess the presence of rivaroxaban? Transfus Apher Sci 2016;55: 212-215.
13. Van Ryn J, Stangier J, Haertter S et al. Dabigatran etexilate – a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost 2010;103:1116–1127.
14. Stangier J, Feuring M. Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentration of dibigatran. Blood Coagul Fibrinolysis. 2012;23:138-143.
15. Samama MM, Contant G, Spiro TE, Perzborn E et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 2012;107:371-387.
16. Mackie I, Cooper P, Lawrie A et al. British Committee for Standards in Haematology. Guidelines on the laboratory aspects of assays used in haemostasis and thrombosis. Int J Lab Hematol 2013;35:1–13.
17. Gosselin RC, Adcock DM. The laboratory's 2015 perspective on direct oral anticoagulant testing. J Thromb Haemost 2016;14:886-893.
18. Schmitz EM, Boonen K, van den Heuvel DJ et al. Determination of dabigatran, rivaroxaban and apixaban by ultra-performance liquid chromatography - tandem mass spectrometry (UPLC-MS/MS) and coagulation assays for therapy monitoring of novel direct oral anticoagulants. J Thromb Haemost 2014;12 :1636-1646.
19. Levy JH, Ageno W, Chan NC et al. When and how to use antidotes for the reversal of direct oral anticoagulants: guidance from the SSC of the ISTH. J Thromb Haemost 2016;14:623–627.
20. Pollack CV Jr, Reilly PA, Eikeboom J et al. Idaricizumab for dabigatran reversal. N Engl J Med 2015;373:511-520.
21. Lippi G, Favaloro EJ. Recent guidelines and recommendations for laboratory assessment of the direct oral anticoagulants (DOACs): is there consensus? Clin Chem Lab Med 2015;53:185-197.
22. Favaloro EJ, Lippi G. Laboratory testing in the era of direct or non-vitamin K antagonist oral anticoagulants: a practical guide to measuring their activity and avoiding diagnostic errors. Semin Thromb Hemost 2015;41:208-227.
23. Mani H, Rohde G, Stratmann, G et al. Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost 2012;108:191–198

 

NOTICE OF ANNUAL GENERAL MEETING

Download the AGM 2016 Notice

---

NOTICE is hereby given that the 25th Annual General Meeting (AGM) of The Hong Kong College of Pathologists will be held at the Pao Yue Kong Auditorium, the Hong Kong Academy of Medicine Jockey Club Building, 99 Wong Chuk Hang Road, Aberdeen, Hong Kong on 26 November 2016 at 5:00 p.m. with the following agenda:

1. To confirm the minutes of the 24th AGM held on 28 November 2015 
2. To deal with any business arising from the minutes
3. To receive the Report of the Council on College activities (2015-2016)
4. To receive the Auditor’s Report and Financial Statements for the period from 1 July 2015 to 30 June 2016 
5. As special business, to consider and, if thought fit, to pass the following Resolution which will be proposed as a Special Resolution:-

• SPECIAL RESOLUTION
• THAT:
• the new articles of association in the form produced to the meeting and watermarked “Amended”, and initialled by the Chairman of the meeting for the purpose of identification, (“New Articles”), be and are hereby approved and adopted as the articles of association of the College in substitution for and to the exclusion of the articles of association of the College in force immediately before the passing of this Special Resolution.
• (please see Annex)

6. To re-appoint Auditor
7. To re-appoint Honorary Legal Advisor
8. To elect Office Bearers and Council Members
9. Any other business

Dated the 20th day of October 2016.

By Order of the Council

TANG Wai Lun
Registrar

Programme of the 25th Annual General Meeting

---

26 November 2016, Saturday

Hong Kong Academy of Medicine Jockey Club Building, 99 Wong Chuk Hang Road, Aberdeen, Hong Kong

Download the AGM 2016 Timetable

---

1:00 p.m. – 4:30 p.m.	The 12th Trainee Presentation Session
5:00 p.m. – 5:45 p.m.	The 25th Annual General Meeting
5:45 p.m. – 6:00 p.m.	Reception
6:00 p.m. – 6:50 p.m.	Conferment Ceremony Admission of New Fellows and Members and Presentation of Fellowship and Membership Certificates Conclusion of Conferment Ceremony
6:50 p.m. – 7:00 p.m.	Group Photo of Stage Party
7:00 p.m. – 8:00 p.m.	The 25th T. B. Teoh Foundation Lecture: “Digital Workflow in Anatomical Pathology – On Track to Patient Safety and Beyond” Dr. LEE Kam Cheong Consultant Pathologist Department of Pathology Princess Margaret Hospital Hong Kong
8:00 p.m. – 10:00 p.m.	Chinese Banquet Dinner

 

After the revamp of the classic website, we need to update the QAP webpage to fit the new system. Below is a brief introduction that may help users transiting to the new platform: 

1. The new webpgae is password protected, and the traditional secret code for amendment will be depreciated
2. The password is set to be identifical to your QAP participation code.
3. You are strongly advised to update the password after your first login by clicking your user icon in the left upper corner of the top menu.
4. Your QAP history will be tabulated out once you logged in.
5. You can submit your answer through the QAP answer form by clicking the link at the left upper corner of the top menu.
6. Your submission will be visible on the mainpage once you refresh the page.
7. You can amend the result by re-input the QAP case through the same QAP ansver form. The old entry will be idntified by the QAP question number (APXXX).

The deadline of submission o f the current round will be 31 October. Sorry for the delay in launching the input form. Further enhancement of the webpage is also in progress.

Webmaster

 

Fellowship Assessment:

Exam No.	Result
E16201	PASS
E16202	PASS
E16203	FAIL
E16204	PASS
E16205	PASS
E16206	PASS
E16207	FAIL
E16208	FAIL
E16209	PASS
E16210	PASS
E16211	PASS
E16212	FAIL
E16213	FAIL
E16214	PASS

 

Membership Examination:

 

Exam No.	Result
E16101	FAIL
E16102	FAIL
E16103	FAIL
E16104	PASS
E16105	PASS
E16106	FAIL
E16107	PASS
E16108	PASS

 

Newborn Screening: Past, Present and the Future

Volume 11, Issue 2 August 2016  (download full article in pdf)

Editorial note:

In this topical update, Dr Chloe Mak reviews the history and development of newborn screening, in particular for Hong Kong. Both benefits and limitations of expanded newborn screening were discussed. The latest pilot screening programme, as stipulated in the Policy Address by Chief Executive, was also illustrated. We welcome any feedback or suggestions. Please direct them to Dr. Sammy Chen (e-mail: chenpls@ha.org.hk) of Education Committee, the Hong Kong College of Pathologists. Opinions expressed are those of the authors or named individuals, and are not necessarily those of the Hong Kong College of Pathologists. 

 

Dr MAK Miu Chloe 

Department of Pathology, Princess Margaret Hospital 

 

 

 

Reference

 

 

College Written Exam 2016 (Council Meeting 14 July 2016)

Results of College Written Exam in Chemical Pathology and Clinical Microbiology & Infection 2016

EXAM NO.	RESULT
E16206	PASS
E16207	FAIL
E16209	PASS
E16211	PASS

Candidates who failed in written exam cannot proceed further in Fellowship Assessment in 2016.

Passed candidates can proceed further in Fellowship Assessment in 2016.

Volume 25, Issue 2 (click here to download the full pdf version)

Message from the President

Volume 25, Issue 1 (click here to download the full pdf version)

Message from the President

We are honoured to stand on the shoulders of giants so that we can continue to enhance the development of pathology based on the achievements of our senior Fellows and colleagues. In this newsletter, tributes are paid to two distinguished pathologists who have contributed tremendously to the development of pathology in Hong Kong. Professor Sir Roddy MACSWEEN and Professor Li Chong CHAN left us in the winter of 2015. This is a personal loss to me, as I have been fortunate enough to have worked with and learnt from them for decades. To express our appreciation and grieve, Professor Faith HO and Professor John NICHOLLS, with the help of Fellows, colleagues and friends, have contributed two articles to pay tributes to these two giants in the eld of pathology.

Indeed, pathology is facing signi cant challenges, from manpower shortage to technological advancement and raised expectations from community. Our College will continue to safeguard the standard of our profession and quality of service to our patients. To achieve this, our College will enhance representation in various local task forces and committees so that our views can be heard. A Task Force on Training for Genetics and Genomics, led by TEC Chairman Dr Michael CHAN, with membership including Chief Examiners and Specialty Board Chairmen, is nalizing the preparation for establishing the post-specialty Fellowship in Genetic and Genomic Pathology.

Introduction of pathology to the general public continues to be enhanced through the International Pathology Day. Last year, we have focused on high school students and a two days’ workshop was conducted with great success. I must thank Dr Michael WONG and the team of young pathologists who made such success possible.

We continue our collaboration with the Hong Kong Academy of Medicine and our sister Colleges. Internationally, I participated in the International Liaison of Pathology Presidents (ILPP) meeting in Melbourne so that knowledge and views can be shared with international pathology professionals.

In 2016, the quinquennial ( ve-yearly) inspection of laboratories for training of the various specialties will be conducted. This is an enormous exercise that demands joint e ort of the large number of inspectors involved. I would like to thank in advance the great contribution from all the Educational Supervisors, inspectors and particularly the Convenors for this inspection exercise.

Professor CHEUNG NgaYin,Annie May 2016

Dear Fellows and CMECPD Activities Organizers,

Kindly noted that the attendaance records for CMECPD activites are updated and please download the relevant attendance record form here.

Thank you very much for your attention.

Webmaster

18 April 2016